PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17683387-2 2007 We report an elderly patient with C-ALCL which recurred after cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy, but was effectively treated with the third-generation etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) regimen. Etoposide 190-199 DNA damage inducible transcript 3 Homo sapiens 121-125 24141009-0 2014 High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma. Etoposide 10-19 DNA damage inducible transcript 3 Homo sapiens 208-212 23750173-0 2013 Fatal Interstitial Pneumonitis Rapidly Developed after the First Cycle of CHOP with Etoposide Combination Chemotherapy in a Patient with Lymphoma. Etoposide 84-93 DNA damage inducible transcript 3 Homo sapiens 74-78 17579865-1 2008 BACKGROUND: The addition of etoposide to the CHOP protocol (CHOEP) has been shown to improve outcome in patients with aggressive non-Hodgkin"s lymphoma. Etoposide 28-37 DNA damage inducible transcript 3 Homo sapiens 45-49 12090052-2 2002 A 39-year-old woman with non-resectable mesenteric malignant lymphoma obtained a better QOL and outcome from prolonged oral administration of low-dose etoposide as a maintenance therapy after CHOP therapy. Etoposide 151-160 DNA damage inducible transcript 3 Homo sapiens 192-196 14653077-5 2003 The CR rate and 5-year survival rate of patients who were treated by the scheme of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) were higher than those treated by the scheme of cyclophosphamide, vincristine, prednisone and etoposide (COP + VP16) (P < 0.05). Etoposide 242-251 DNA damage inducible transcript 3 Homo sapiens 142-146 14653077-5 2003 The CR rate and 5-year survival rate of patients who were treated by the scheme of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) were higher than those treated by the scheme of cyclophosphamide, vincristine, prednisone and etoposide (COP + VP16) (P < 0.05). Etoposide 259-263 DNA damage inducible transcript 3 Homo sapiens 142-146 16518603-1 2006 Our aim was to study the efficacy of the addition of etoposide and bleomycin to a [cyclophosphamide (CPA), doxorubicin (DXR), vincristine (VCR), and prednisone (PDN)] CHOP-like regimen for the treatment of aggressive lymphoma. Etoposide 53-62 DNA damage inducible transcript 3 Homo sapiens 167-171 16518603-13 2006 The addition of etoposide and bleomycin to CHOP therapy may enhance the effect of CHOP therapy for aggressive lymphoma. Etoposide 16-25 DNA damage inducible transcript 3 Homo sapiens 43-47 16518603-13 2006 The addition of etoposide and bleomycin to CHOP therapy may enhance the effect of CHOP therapy for aggressive lymphoma. Etoposide 16-25 DNA damage inducible transcript 3 Homo sapiens 82-86 14645667-5 2003 Increased expression of GADD153 raised the background level of apoptosis and increased apoptosis induced by fenretinide or the chemotherapeutic drugs cisplatin and etoposide. Etoposide 164-173 DNA damage inducible transcript 3 Homo sapiens 24-31 12815281-8 2003 Based on the up-regulations observed at the mRNA level, it is speculated that etoposide-induced apoptosis in the HL-60 cells proceeds via pathways involving factors such as TNFalpha, IGFBP3, SAPK1, AP-1 and GADD153/CHOP10. Etoposide 78-87 DNA damage inducible transcript 3 Homo sapiens 207-214 12815281-8 2003 Based on the up-regulations observed at the mRNA level, it is speculated that etoposide-induced apoptosis in the HL-60 cells proceeds via pathways involving factors such as TNFalpha, IGFBP3, SAPK1, AP-1 and GADD153/CHOP10. Etoposide 78-87 DNA damage inducible transcript 3 Homo sapiens 215-221 11345781-3 2001 CHOP + etoposide (CHOP-E) was used as an initial chemotherapy and as a chemotherapy agent for the purpose of cell harvesting. Etoposide 7-16 DNA damage inducible transcript 3 Homo sapiens 18-22 9044846-0 1997 Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide. Etoposide 104-113 DNA damage inducible transcript 3 Homo sapiens 10-17 9818704-4 1998 She received chemotherapy with the CHOP-etoposide regimen, resulting in partial remission. Etoposide 40-49 DNA damage inducible transcript 3 Homo sapiens 35-39 9044846-4 1997 We have investigated the relationships between gadd153 gene expression and apoptosis induction in four human leukemic cell lines with different sensitivities to apoptosis induced by etoposide (VP-16), a topoisomerase II inhibitor. Etoposide 182-191 DNA damage inducible transcript 3 Homo sapiens 47-54 32112707-5 2020 In a small sample size, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) achieved better outcomes than a regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Etoposide 24-33 DNA damage inducible transcript 3 Homo sapiens 231-235 7563607-9 1995 After therapy with plasmapheresis and the CHOP regimen, he was given etoposide. Etoposide 69-78 DNA damage inducible transcript 3 Homo sapiens 42-46 35486884-9 2022 Use of regimens other than R-CHOP was associated with a higher risk of death/progression for patients with DLBCL (rituximab, ifosfamide, carboplatin, and etoposide/ifosfamide, carboplatin, and etoposide) and FL (CHOP). Etoposide 154-163 DNA damage inducible transcript 3 Homo sapiens 212-216